Suppr超能文献

哪些静脉血栓栓塞患者需要长期抗凝治疗,以及用什么药物进行治疗?

Who should get long-term anticoagulant therapy for venous thromboembolism and with what?

机构信息

Ottawa Blood Disease Centre, Ottawa Hospital, Ottawa, Ontario, Canada.

Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada; and.

出版信息

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):426-431. doi: 10.1182/asheducation-2018.1.426.

Abstract

After an initial 3 to 6 months of anticoagulation for venous thromboembolism (VTE), clinicians and patients face an important question: "Do we stop anticoagulants or continue them indefinitely?" The decision is easy in some scenarios (eg, stop in VTE provoked by major surgery). In most scenarios, which are faced on a day-to-day basis in routine practice, it is a challenging decision because of uncertainty in estimates in the long-term risks (principally major bleeding) and benefits (reducing recurrent VTE) and the tight trade-offs between them. Once the decision is made to continue, the next question to tackle is "Which anticoagulant?" Here again, it is a difficult decision because of the uncertainty with regard to estimates of efficacy and the safety of anticoagulant options and the tight trade-offs between choices. We conclude with the approach that we take in our clinical practice.

摘要

在静脉血栓栓塞症 (VTE) 初始抗凝治疗 3 至 6 个月后,临床医生和患者面临一个重要问题:“我们是否停止抗凝治疗,还是无限期地继续抗凝?”在某些情况下(例如,由大手术引起的 VTE),这个决定很容易做出。但在大多数情况下,这是一个具有挑战性的决定,因为长期风险(主要是大出血)和获益(减少复发性 VTE)的估计存在不确定性,并且两者之间存在严格的权衡。一旦决定继续抗凝,下一个需要解决的问题是“选择哪种抗凝剂?”这同样也是一个艰难的决定,因为对于抗凝药物疗效和安全性的估计存在不确定性,并且选择之间存在严格的权衡。我们将以我们在临床实践中采取的方法作为结论。

相似文献

1
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):426-431. doi: 10.1182/asheducation-2018.1.426.
2
Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Blood Adv. 2018 Nov 13;2(21):3081-3087. doi: 10.1182/bloodadvances.2018020230.
3
Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit.
Blood Rev. 2010 Jul-Sep;24(4-5):171-8. doi: 10.1016/j.blre.2010.06.001. Epub 2010 Jul 14.
4
[Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
Rev Pneumol Clin. 2008 Dec;64(6):305-15. doi: 10.1016/j.pneumo.2008.09.007. Epub 2008 Nov 18.
7
Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
Br J Haematol. 2012 Aug;158(4):433-41. doi: 10.1111/j.1365-2141.2012.09196.x. Epub 2012 Jun 26.
9
Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Thromb Res. 2014 Oct;134(4):807-13. doi: 10.1016/j.thromres.2014.07.027. Epub 2014 Jul 23.

引用本文的文献

1
Portal vein thrombosis due to inherited combined deficiency of protein C and S in a young adult: A case report.
Radiol Case Rep. 2024 Sep 24;19(12):6235-6240. doi: 10.1016/j.radcr.2024.09.052. eCollection 2024 Dec.
2
Massive Pulmonary Embolism Related to a Patient With Heart Failure Secondary to Stress Cardiomyopathy: A Case Report.
Cureus. 2024 Jan 26;16(1):e52985. doi: 10.7759/cureus.52985. eCollection 2024 Jan.
3
Assessing the performance of genetic risk score for stratifying risk of post-sepsis cardiovascular complications.
Front Cardiovasc Med. 2023 Feb 28;10:1076745. doi: 10.3389/fcvm.2023.1076745. eCollection 2023.

本文引用的文献

1
Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism.
Blood. 2018 May 10;131(19):2151-2160. doi: 10.1182/blood-2017-09-805689. Epub 2018 Feb 28.
2
What have we learned from real-world NOAC studies in venous thromboembolism treatment?
Thromb Res. 2018 Mar;163:83-91. doi: 10.1016/j.thromres.2018.01.034. Epub 2018 Feb 6.
3
Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study.
J Thromb Haemost. 2018 Apr;16(4):680-688. doi: 10.1111/jth.13960. Epub 2018 Feb 28.
4
Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism.
N Engl J Med. 2017 Mar 30;376(13):1211-1222. doi: 10.1056/NEJMoa1700518. Epub 2017 Mar 18.
6
Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Thromb Haemost. 2017 Apr 3;117(4):784-793. doi: 10.1160/TH16-11-0830. Epub 2017 Feb 2.
7
The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study.
J Thromb Haemost. 2016 Dec;14(12):2402-2409. doi: 10.1111/jth.13524. Epub 2016 Nov 19.
8
Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment.
Eur Respir J. 2016 Nov;48(5):1369-1376. doi: 10.1183/13993003.00280-2016. Epub 2016 Jul 28.
9
Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.
J Thromb Haemost. 2016 Jul;14(7):1480-3. doi: 10.1111/jth.13336. Epub 2016 Jun 7.
10
Long-term risk of venous thrombosis after stopping anticoagulants for a first unprovoked event: A multi-national cohort.
Thromb Res. 2016 Jul;143:152-8. doi: 10.1016/j.thromres.2016.03.028. Epub 2016 Mar 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验